See more : Banca Sistema S.p.A. (0R9H.L) Income Statement Analysis – Financial Results
Complete financial analysis of Neoleukin Therapeutics, Inc. (NLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neoleukin Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Integra Engineering India Limited (INTEGRAEN.BO) Income Statement Analysis – Financial Results
- Meridian Energy Limited (MDDNF) Income Statement Analysis – Financial Results
- Kape Technologies PLC (KAPE.L) Income Statement Analysis – Financial Results
- Universe Entertainment and Culture Group Company Limited (1046.HK) Income Statement Analysis – Financial Results
- Macquarie Telecom Group Limited (MAQ.AX) Income Statement Analysis – Financial Results
Neoleukin Therapeutics, Inc. (NLTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neoleukin.com
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 41.13M | 39.16M | 24.34M | 4.42M | 41.79M | 36.27M | 28.38M | 15.80M | 18.08M | 7.54M | 6.05M |
| General & Administrative | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Other Expenses | -42.00K | 6.00K | -44.00K | -8.00K | -445.00K | -39.00K | -43.00K | -369.00K | -254.89K | 0.00 | 64.03K |
| Operating Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Cost & Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Interest Income | 1.58M | 19.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 0.00 |
| Interest Expense | 1.58M | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 461.59K | 42.92K | 9.47K |
| Depreciation & Amortization | 2.61M | 2.28M | -13.84M | 49.59M | 1.04M | 940.00K | 644.00K | -421.00K | 135.95K | 59.57K | 130.78K |
| EBITDA | -56.49M | -60.70M | -47.56M | -21.37M | -31.51M | -50.16M | -37.07M | -21.71M | -24.38M | -9.68M | -7.53M |
| EBITDA Ratio | 0.00% | -1,011,633.33% | -10,546.34% | 0.00% | -126.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -59.10M | -60.70M | -33.73M | -70.96M | -32.62M | -51.12M | -37.65M | -21.34M | -23.57M | -9.38M | -7.66M |
| Operating Income Ratio | 0.00% | -1,011,633.33% | -7,478.49% | 0.00% | -130.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.54M | 6.00K | 7.83M | 1.52M | 1.04M | 936.00K | 643.00K | -520.00K | 487.60K | 641.24K | -9.47K |
| Income Before Tax | -57.56M | -60.69M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M |
| Income Before Tax Ratio | 0.00% | -1,011,533.33% | -7,378.49% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.54M | -2.28M | -8.32M | -7.00K | -1.04M | -940.00K | -644.00K | 421.00K | -222.00 | -5.04K | 42.29K |
| Net Income | -56.02M | -58.42M | -24.96M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -9.30M | -12.14M |
| Net Income Ratio | 0.00% | -973,583.33% | -5,533.48% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EPS Diluted | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| Weighted Avg Shares Out | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
| Weighted Avg Shares Out (Dil) | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -
Neoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript
Neoleukin Therapeutics Announces Year End 2020 Financial Results
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C....
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the...
Neoleukin Therapeutics: De Novo Protein Design Platform
Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX
New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su ch investors are advised to contact Robert S. Willoughby at...
SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal securities laws. On January 8, 2021, Neoleukin announced that "on January 7, 2021,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX
New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su ch investors are advised to contact Robert S. Willoughby at...
Why Neoleukin Therapeutics Stock Is Down Today
The company is experiencing regulatory headwinds.
Source: https://incomestatements.info
Category: Stock Reports